« Return to News | Study Conduct

Cetero sold to investor group, renamed PRACS Institute

Wednesday, June 20, 2012 02:38 PM

Cary, N.C.-based Cetero Research has finalized the sale of the company to its investor group, led by Freeport Financial, following the company’s Chapter 11 bankruptcy filing court approval of the sale.

As part of the new ownership structure, the company’s headquarters will move to Fargo, N.D., and the company has been renamed PRACS Institute.

The board of directors has named three executive appointments to lead operational, financial and new business initiatives. James Carlson, Pharm.D, has been named CEO. Carlson has more than 30 years of experience in early phase research. He co-founded and served as CEO of Cetero Research, based in Fargo, N.D., from 1983 to 2006, where he oversaw the conduct of more than 450 studies per year across a range of therapeutic indications and study types.

Mark Ubert, CPA, MBA, has been named CFO. Ubert joined Cetero in 2009 as corporate controller. John Pottier has been named executive vice president, business development. Joining PRACS from Worldwide Clinical Trials, Pottier previously served in business development roles at Novum Research, Cetero Research and PRACS Institute, after beginning his career at the Clinical Research Foundation, now part of Quintiles Transnational.

Founded in 2004 by a group of corporate finance and capital markets professionals, Freeport Financial provides capital and leveraged finance solutions to middle market companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.